Integrated Filing — IndAS


General information about company

Scrip Code 543329
NSE Symbol WINDLAS
MSEI Symbol NA
ISIN INE0H5O01029
Name of company Windlas Biotech Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 22-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 14-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 22-May-2025   14:30:00
End date and time of board meeting 22-May-2025   16:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-11
Indicate Company website link for updated RPT policy of the Company https://windlas.com/wp-content/uploads/2025/03/Policy-of-Materiality-of-the-Related-Party-Transactions-2nd-Amendment-1.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
NA



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2027050000 7598780000
Other income 49410000 176460000
Total income 2076460000 7775240000
2 Expenses
(a) Cost of materials consumed 33310000 23280000
(b) Purchases of stock-in-trade 1117650000 4910500000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 100950000 -215230000
(d) Employee benefit expense 319270000 1229160000
(e) Finance costs 13270000 43820000
(f) Depreciation, depletion and amortisation expense 83350000 279850000
(f) Other Expenses
1 Power & fuel 57350000 216130000
2 Commission on sales 38880000 99100000
3 Freight and carriage 22690000 86350000
4 Research & Development Expenses 15710000 62510000
5 Traveling Expenses 9640000 33320000
6 Repair & Maintenance 7130000 29310000
7 Advertisement and Publicity 8360000 27870000
8 Lab Testing Expenses 6360000 27430000
9 Security expenses 6170000 20910000
10 Other Expenses 28100000 106990000
Total other expenses 200390000 709920000
Total expenses 1868190000 6981300000
3 Total profit before exceptional items and tax 208270000 793940000
4 Exceptional items 0 0
5 Total profit before tax 208270000 793940000
6 Tax expense
7 Current tax 46060000 182730000
8 Deferred tax -640000 4720000
9 Total tax expenses 45420000 187450000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 162850000 606490000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 162850000 606490000
17 Other comprehensive income net of taxes 1750000 -5430000
18 Total Comprehensive Income for the period 164600000 601060000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 104800000 104800000
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve 4953080000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 7.77 29.03
Diluted earnings (loss) per share from continuing operations 7.69 28.71
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 7.77 29.03
Diluted earnings (loss) per share from continuing and discontinued operations 7.69 28.71
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1954940000
Capital work-in-progress 32010000
Investment property 0
Goodwill 0
Other intangible assets 278930000
Intangible assets under development 21180000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 0
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 42580000
Total non-current financial assets 42580000
Deferred tax assets (net) 2830000
Other non-current assets 20740000
Total non-current assets 2353210000
2 Current assets
Inventories 813840000
Current financial asset
Current investments 2233690000
Trade receivables, current 1668630000
Cash and cash equivalents 4210000
Bank balance other than cash and cash equivalents 155030000
Loans, current 0
Other current financial assets 10000000
Total current financial assets 4071560000
Current tax assets (net) 32800000
Other current assets 333060000
Total current assets 5251260000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 7604470000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 104800000
Other equity 4953080000
Total equity attributable to owners of parent 5057880000
Non controlling interest
Total equity 5057880000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 23510000
Total non-current financial liabilities 23510000
Provisions, non-current 28840000
Deferred tax liabilities (net) 0
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 52350000
Current liabilities
Current financial liabilities
Borrowings, current 271170000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 120270000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1552100000
Total Trade payable 1672370000
Other current financial liabilities 407630000
Total current financial liabilities 2351170000
Other current liabilities 127490000
Provisions, current 15580000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 2494240000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 2546590000
Total equity and liabilites 7604470000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit plans- gain/(loss) 2330000 -7260000
Total Amount of items that will not be reclassified to profit and loss 2330000 -7260000
2 Income tax relating to items that will not be reclassified to profit or loss 580000 -1830000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 1750000 -5430000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 793940000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 43820000
Adjustments for decrease (increase) in inventories -191950000
Adjustments for decrease (increase) in trade receivables, current -308030000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -70890000
Adjustments for decrease (increase) in other non-current assets -50000
Adjustments for other financial assets, non-current -650000
Adjustments for other financial assets, current -4780000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 361250000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 80800000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 279850000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 1070000
Adjustments for provisions, non-current 5630000
Adjustments for other financial liabilities, current 41320000
Adjustments for other financial liabilities, non-current -800000
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 15450000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) -150880000
Other adjustments for non-cash items 26770000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 97030000
Net cash flows from (used in) operations 890970000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 208650000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 682320000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 1970000
Purchase of property, plant and equipment 521940000
Proceeds from sales of investment property 0
Purchase of investment property 348550000
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets -111610000
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 16270000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) investing activities -740640000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 44260000
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 270080000
Repayments of borrowings 0
Payments of lease liabilities 145440000
Dividends paid 114950000
Interest paid 43820000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities 10130000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -48190000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -48190000
Cash and cash equivalents cash flow statement at beginning of period 52400000
Cash and cash equivalents cash flow statement at end of period 4210000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 S S Kothari Mehta & Co LLP Yes 31-Aug-2025


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Windlas Biotech Limited Mr. Ashok Windlass Wholetime Director Remuneration 7800000 Approved 7800000 1300000 1300000
2 Windlas Biotech Limited Mr. Hitesh Windlass Managing Director Remuneration 4350000 Approved 4350000 730000 730000
3 Windlas Biotech Limited Mr. Manoj Windlass Jt. Managing Director Remuneration 4350000 Approved 4350000 730000 730000
4 Windlas Biotech Limited Mr.Pawan Kumar Sharma Executive Director Remuneration 3290000 Approved 3290000 550000 1240000
5 Windlas Biotech Limited Ms. Komal Gupta CEO & CFO Remuneration 10630000 Approved 10630000 1770000 5440000
6 Windlas Biotech Limited Mr. Ananta Narayan Panda Company Secretary Remuneration 1480000 Approved 1480000 250000 430000
7 Windlas Biotech Limited Mr. Hitesh Windlass Managing Director Any other transaction Commission on Profit 9000000 Approved 9000000 0 9000000
8 Windlas Biotech Limited Mr. Manoj Windlass Jt. Managing Director Any other transaction Commission on Profit 9000000 Approved 9000000 0 9000000
9 Windlas Biotech Limited Mr. Ashok Windlass Wholetime Director Any other transaction Rent 980000 Approved 980000 160000 160000
10 Windlas Biotech Limited Mr. Hitesh Windlass Managing Director Any other transaction Rent 980000 Approved 980000 160000 160000
11 Windlas Biotech Limited Mr. Manoj Windlass Jt. Managing Director Any other transaction Rent 970000 Approved 970000 170000 170000
12 Windlas Biotech Limited Mr. Ashok Windlass Wholetime Director Any other transaction Refund of Security Deposit -880000 Approved -880000 1070000 180000
13 Windlas Biotech Limited Mr. Hitesh Windlass Managing Director Any other transaction Refund of Security Deposit -880000 Approved -880000 1070000 180000
14 Windlas Biotech Limited Mr. Manoj Windlass Jt. Managing Director Any other transaction Refund of Security Deposit -890000 Approved -890000 1060000 170000
15 Windlas Biotech Limited Mr. Gaurav Gulati Independent Director Any other transaction Director sitting fee 280000 Approved 280000 0 0
16 Windlas Biotech Limited Mr. Vivek Dhariwal Independent Director Any other transaction Director sitting fee 170000 Approved 170000 0 0
17 Windlas Biotech Limited Mr. Srinivasan Venkataraman Independent Director Any other transaction Director sitting fee 200000 Approved 200000 0 0
18 Windlas Biotech Limited Mr.Pawan Kumar Sharma Executive Director Any other transaction Share Appplication Throuhg ESOP 1030000 Approved 1030000 0 0
19 Windlas Biotech Limited Mr. Ananta Narayan Panda Company Secretary Any other transaction Share Appplication Throuhg ESOP 100000 Approved 100000 0 0
20 Windlas Biotech Limited Mr.Pawan Kumar Sharma Executive Director Any other transaction ESOP Expenses 560000 Approved 560000 0 0
21 Windlas Biotech Limited Mr. Ananta Narayan Panda Company Secretary Any other transaction ESOP Expenses 60000 Approved 60000 0 0
Total value of transaction during the reporting period 52580000





Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt